BLCO TOR Week ended 31 Jul 2026

Weekly Investor Report

Bausch + Lomb Corporation · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 23.66 CAD
4.1% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is 4.1% above the Trend Line and sits at 70.6% of its 52-week range. The latest completed week returned 4.1%, after a -3.6% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100.

Setup score 49 out of 100
Latest Close 23.66 CAD 31 Jul 2026
1W Return 4.1% latest completed week
4W Return -3.6% short-term follow-through
12W Return 7.0% quarterly tape
Trend Breadth 53.8% 28 of 52 weeks active
Volume Ratio 1.8x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.1% Latest completed week; four-week move -3.6%. Indicator stack 30/77 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 52/100 24 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 4.1% above the Trend Line and sits at 70.6% of its 52-week range. The latest completed week returned 4.1%, after a -3.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3412-week average 0.26

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.34Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -3.6% over four weeks, 7.0% over 12 weeks, and 26.8% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.1%
4W-3.6%
12W7.0%
26W7.1%
52W26.8%
Active trend streak0 weeks
Active weeks in one year28
Trend breadth53.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.59Latest activity-pressure read.
Pressure change206.2%Four-week change in activity pressure.
Leadership-2.29Latest relative-leadership reading.
RS change-404.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength8/100Blend of value, momentum, and quality. Underlying universe rank 93; rank 1 is best.
Value23/100Relative valuation strength. Underlying universe rank 78; rank 1 is best.
Quality14/100Profitability and accounting quality. Underlying universe rank 87; rank 1 is best.
Momentum29/100Medium-term price momentum. Underlying universe rank 72; rank 1 is best.
Growth65/100Revenue and earnings growth. Underlying universe rank 36; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework11/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.6x
Market value relative to trailing revenue.
EV / EBITDA
20.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
0.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
60.6%
Gross profit retained from each unit of revenue.
Operating margin
5.9%
Operating profit retained from revenue.
Free-cash-flow margin
0.0%
Free cash flow generated from revenue.
Return on invested capital
2.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
6.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
7.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 24 relevant articles.

3 positive · 20 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-7.9%Distance below the 52-week high.
13-week volatility4.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+11.8%Week of 26 Jun.
Worst week-6.8%Week of 10 Jul.
Latest week+4.1%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains6
Flat weeks0
Modest losses10
Sharp losses4
Recent vol4.4%13-week weekly-return volatility.
Base vol4.0%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew3.7% / -2.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

IndustryCA Medical Instruments & Supplies
4-week rank1 / 1
Group average-3.6%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD100.0%positive activity pressure
RS0.0%positive relative leadership

Four-week leaders

BLCO · TOR-3.6%
08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape47/100

Trend, activity pressure, participation, and risk combine to a 47/100 tape read.

 Indicator analysis23/100

Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 1/12.

Activity pressure 0.34; No reversal markers Factors17/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 53; Small Cap Core rank 75 SVQF11/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 266.5 of 300 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 24 relevant articles.

Bausch + Lomb (BLCO) Stock Rallies On Margin Gains As Losses Narrow Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202623.66 CAD4.1%22.72 CAD22.00 CAD0.59-2.2913.4KOff
24 Jul 202622.72 CAD0.1%22.69 CAD22.01 CAD0.62-6.607.7KOff
17 Jul 202622.69 CAD-0.9%22.71 CAD22.03 CAD0.51-6.639.9KOff
10 Jul 202622.89 CAD-6.8%22.70 CAD22.06 CAD0.00-6.0710.7KOff
3 Jul 202624.55 CAD6.5%22.71 CAD22.09 CAD-0.560.7513.2KOff
26 Jun 202623.05 CAD11.8%22.65 CAD22.10 CAD-1.25-4.694.6KOff
19 Jun 202620.61 CAD-2.3%22.64 CAD22.12 CAD-1.59-14.69400Off
12 Jun 202621.10 CAD-2.5%22.67 CAD22.15 CAD-1.49-12.60500Off
5 Jun 202621.64 CAD0.1%22.69 CAD22.19 CAD-1.36-9.093.5KOff
29 May 202621.62 CAD-1.5%22.70 CAD22.21 CAD-1.17-10.046.9KOff
22 May 202621.96 CAD-0.1%22.68 CAD22.22 CAD-1.03-7.775.7KOff
15 May 202621.98 CAD-0.6%22.68 CAD22.24 CAD-1.01-5.847.9KOff
8 May 202622.11 CAD0.3%22.65 CAD22.27 CAD-0.92-5.9111.2KOff
1 May 202622.04 CAD1.7%22.58 CAD22.29 CAD-0.92-5.6315.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.